786 related articles for article (PubMed ID: 3894520)
1. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
3. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
[TBL] [Abstract][Full Text] [Related]
4. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
Nakajima H; Izumi Y; Sugihara S; Satoh Y; Isumi S; Gotoh T; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):201-8. PubMed ID: 3119213
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
7. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
Yoshioka T; Sato S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
[TBL] [Abstract][Full Text] [Related]
10. Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.
Mitani M; Matsumoto T; Mori K; Miake S; Himeno K; Nomoto K
J Clin Lab Immunol; 1985 Oct; 18(2):97-101. PubMed ID: 3935795
[TBL] [Abstract][Full Text] [Related]
11. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 enhancement of lymphokine secretion by T lymphocytes: analysis of established clones and primary limiting dilution microcultures.
Kelso A; MacDonald HR; Smith KA; Cerottini JC; Brunner KT
J Immunol; 1984 Jun; 132(6):2932-8. PubMed ID: 6233365
[TBL] [Abstract][Full Text] [Related]
13. A dissociated induction of MCF-producing and MAF-producing T cells specific for Listeria monocytogenes in the in vitro primary culture system.
Muramori K; Mitsuyama M; Handa T; Serushago BA; Nomoto K
Immunology; 1991 Mar; 72(3):373-9. PubMed ID: 1902819
[TBL] [Abstract][Full Text] [Related]
14. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.
Kelso A; Glasebrook AL; Kanagawa O; Brunner KT
J Immunol; 1982 Aug; 129(2):550-6. PubMed ID: 7045227
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte-induced macrophage cytotoxicity. Production of specific macrophage arming factor by sensitized Lyt 1+2+ T-lymphocytes.
Pels E; De Weger RA; Den Otter W
Int Arch Allergy Appl Immunol; 1984; 74(2):140-6. PubMed ID: 6609130
[TBL] [Abstract][Full Text] [Related]
16. Interferon-induced enhancement of macrophage-mediated tumor cytolysis and its difference from activation by lymphokines.
Boraschi D; Tagliabue A
Eur J Immunol; 1981 Feb; 11(2):110-4. PubMed ID: 6163639
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
18. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis.
Liew FY; Millott S; Li Y; Lelchuk R; Chan WL; Ziltener H
Eur J Immunol; 1989 Jul; 19(7):1227-32. PubMed ID: 2503386
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells.
Sato S; Fukuzawa M; Nakajima H; Ogata M; Kosugi A; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Nov; 76(11):1099-106. PubMed ID: 2935516
[TBL] [Abstract][Full Text] [Related]
20. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
Kurata S; Tsuchiya T; Norimura T; Yamashita U
J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
